Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Conference Correspondent
Effect of Prior Chemotherapy Regimens on Rucaparib Treatment in Platinum-Sensitive Recurrent Ovarian Carcinoma
ESMO 2018
,
ESMO
Conference Correspondent
— October 19, 2018
Progression-free survival associated with rucaparib is not affected by the number of prior chemotherapy regimens.
Read Article
A Phase 2 Study of Durvalumab, a PD-L1 Inhibitor, and Olaparib in Recurrent Ovarian Cancer
ESMO 2018
,
ESMO
Conference Correspondent
— October 19, 2018
Results suggest that the combination of durvalumab and olaparib was well-tolerated and had clinical activity in heavily pretreated,
BRCA
-wildtype ovarian cancer patients.
Read Article
A Phase 2 Trial of Combination Nivolumab and Bevacizumab in Recurrent Ovarian Cancer
ESMO 2018
,
ESMO
Conference Correspondent
— October 19, 2018
This combination of antiangiogenic and immune checkpoint blockade has clinical activity in women with recurrent ovarian cancer.
Read Article
Psychological Support vs Standard of Care Following Chemotherapy for Ovarian Cancer
ESMO 2018
,
Ovarian Cancer
,
ESMO
Conference Correspondent
— October 18, 2018
Patients receiving psychological support in the OVPSYCH2 randomized study showed reduced fear of progression compared with those without support.
Read Article
Carboplatin/Pegylated Liposomal Doxorubicin/Bevacizumab vs Carboplatin/Gemcitabine/Bevacizumab in Patients with Recurrent Ovarian Cancer
ESMO 2018
,
ESMO
Conference Correspondent
— October 18, 2018
The novel combination of carboplatin, pegylated liposomal doxorubicin, and bevacizumab has a promising safety and efficacy profile.
Read Article
Phase 3 Trial of Lurbinectedin vs Pegylated Liposomal Doxorubicin or Topotecan in Platinum-Resistant Ovarian Cancer Patients
ESMO 2018
,
Ovarian Cancer
,
ESMO
Conference Correspondent
— October 18, 2018
Promising safety results from the CORAIL trial suggest a place for lurbinectedin in treating platinum-resistant ovarian cancer.
Read Article
A Phase 1/2 Study of Chemo-Immunotherapy with Durvalumab and Pegylated Liposomal Doxorubicin (PLD) in Platinum-Resistant Recurrent Ovarian Cancer
ESMO 2018
,
Ovarian Cancer
,
ESMO
Conference Correspondent
— October 18, 2018
Durvalumab/PLD combination shows promising efficacy and a tolerable safety profile in women with platinum-resistant ovarian cancer.
Read Article
Olaparib Maintenance Therapy in Patients with Platinum-Sensitive Relapsed Ovarian Cancer and Stable Disease
ESMO 2018
,
Ovarian Cancer
,
ESMO
Conference Correspondent
— October 18, 2018
Olaparib maintenance may prolong progression-free survival in patients, regardless of the number of previous platinum-based chemotherapies.
Read Article
Meta-Analysis of PARP-Inhibitor–Associated Gastrointestinal and Hepatic Toxicities
ESMO 2018
,
ESMO
Conference Correspondent
— October 18, 2018
Early intervention and supportive care for gastrointestinal and hepatic toxicities should be considered for patients receiving PARP inhibitors.
Read Article
Clinical Characteristics of Ovarian Cancer Relapse in BRCA1/2 Germ-Line Mutation Carriers and Noncarriers
ESMO 2018
,
Ovarian Cancer
,
ESMO
Conference Correspondent
— October 18, 2018
Analysis of high-grade serous ovarian cancers suggests that
BRCA1/2
-driven cancers have a more favorable mode of relapse than sporadic cancers.
Read Article
Page 13 of 44
10
11
12
13
14
15
16
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma